Prostate Cancer Clinical Research
Back to Oncology/Cancer Clinical Trials Main Page
CPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
|---|---|---|---|
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma. RTOG 0232 Visit the Intermediate Risk Prostatic Carcinoma study on ClinicalTrials.gov. | Selected Subjects with intermediate risk Prostatic Carcinoma | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with high-Risk, Clinically Localized Prostate Cancer. CALGB 90203 Visit the Clinically Localized Prostate Cancerstudy on ClinicalTrials.gov. | Subjects who have histologic documentation of prostatic cancer | Open |
| Principal Investigator: Ari Baron, MD Contact: Anna Ruiz 415-600-3214 Email ruizac@cpmcri.org | A Phase III, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Who Have Failed Docetaxel-Based Chemotherapy. Cougar Biotechnology COU-AA-301 Visit the Resistant Prostate Cancer study on ClinicalTrials.gov. | Subjects who have been treated with a docetaxel-based chemotherapy and the prostate cancer is progressing | Closed to Enrollment |
updated: 1/29/10
Back to top